The Progressive Supranuclear Palsy Clinical Trial Platform (NCT07173803)
Overview
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen adaptive platform trial designed to evaluate multiple investigational products for the treatment of PSP simultaneously[@nct].
Trial Details
| Field | Value | |-------|-------| | NCT ID | NCT07173803 | | Status | Not Yet Recruiting | | Phase | Platform Trial | | Sponsor | University of Pennsylvania | | Start Date | 2024 | | Duration | Approximately 5 years |
Platform Design
Unlike traditional single-drug trials, this platform trial allows multiple investigational products to be tested in parallel under a single protocol. This approach offers several advantages:
Efficient patient enrollment: Patients can be assigned to different treatment arms based on eligibility
Adaptive design: New treatment arms can be added as evidence emerges
Shared control group: Reduces the number of patients needing placebo allocation
Faster evaluation: Multiple drugs can be tested simultaneously
Investigational Products
AADvac1
AADvac1 is a tau vaccine developed by Axon Neuroscience SE. It targets pathological tau proteins by stimulating the immune system to produce antibodies against them. The vaccine has shown promise in earlier studies for removing toxic tau species from the brain[@axon].
Mechanism: Active immunization with tau peptide conjugated to keyhole limpet hemocyanin (KLH) to generate anti-tau antibodies
...
The Progressive Supranuclear Palsy Clinical Trial Platform (NCT07173803)
Overview
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen adaptive platform trial designed to evaluate multiple investigational products for the treatment of PSP simultaneously[@nct].
Trial Details
| Field | Value | |-------|-------| | NCT ID | NCT07173803 | | Status | Not Yet Recruiting | | Phase | Platform Trial | | Sponsor | University of Pennsylvania | | Start Date | 2024 | | Duration | Approximately 5 years |
Platform Design
Unlike traditional single-drug trials, this platform trial allows multiple investigational products to be tested in parallel under a single protocol. This approach offers several advantages:
Efficient patient enrollment: Patients can be assigned to different treatment arms based on eligibility
Adaptive design: New treatment arms can be added as evidence emerges
Shared control group: Reduces the number of patients needing placebo allocation
Faster evaluation: Multiple drugs can be tested simultaneously
Investigational Products
AADvac1
AADvac1 is a tau vaccine developed by Axon Neuroscience SE. It targets pathological tau proteins by stimulating the immune system to produce antibodies against them. The vaccine has shown promise in earlier studies for removing toxic tau species from the brain[@axon].
Mechanism: Active immunization with tau peptide conjugated to keyhole limpet hemocyanin (KLH) to generate anti-tau antibodies
Previous studies:
Phase 1 trials showed good safety and immunogenicity
Phase 2 trial (Zin万丈-1) evaluated efficacy in AD
LM11A-31
LM11A-31 is a small molecule p75 neurotrophin receptor (p75NTR) modulator developed by Astellas Pharma (formerly known as BMS-902464). It promotes nerve growth factor (NGF) signaling and has demonstrated neuroprotective effects in preclinical models[@longo2013].
Mechanism: Binds to p75NTR, preventing pro-NGF-mediated cell death while promoting TrkA-mediated survival signaling
Previous studies:
Phase 1 trials in AD showed target engagement
Being repositioned for PSP based on preclinical data
Rationale for PSP
Both AADvac1 and LM11A-31 target different aspects of tau pathology:
AADvac1 aims to reduce extracellular tau propagation
LM11A-31 targets neuronal survival pathways affected by tau pathology
The platform design allows for combinatorial insights, as patients can potentially receive both treatments in future iterations.
Scientific Rationale
Why Platform Trials for PSP
Traditional clinical trial designs face significant challenges in PSP:
Small patient population — PSP prevalence is ~5-6 per 100,000, limiting enrollment
Heterogeneous disease — Multiple clinical subtypes respond differently to treatments
Slow progression — Requires long trial durations to detect disease modification
High failure rate — >95% of PSP trials fail to meet primary endpoints
Platform trials address these challenges through:
Master protocols — Single protocol testing multiple interventions
Adaptive design — Ability to drop ineffective arms and add new ones
Shared infrastructure — Reduced overhead per intervention
Efficient enrollment — Patients can be screened for multiple treatment arms
AADvac1 Mechanism
AADvac1 is a tau vaccine developed by Axon Neuroscience SE that targets pathological tau proteins:
Antigen: Recombinant truncated tau peptide conjugated to KLH
Mechanism: Active immunization induces anti-tau antibodies
Target: Extracellular tau aggregates and propagation
The vaccine aims to reduce tau pathology by generating antibodies that:
Bind to extracellular tau aggregates
Prevent uptake by neighboring neurons
Enhance microglial clearance of tau species
LM11A-31 Mechanism
LM11A-31 is a p75 neurotrophin receptor (p75NTR) modulator that promotes neuroprotection:
Target: p75NTR, which mediates pro-apoptotic signaling when bound by pro-NGF
Mechanism: Modulates p75NTR to promote TrkA survival signaling
Neuroprotection: Prevents tau-induced neuronal death
This approach is novel in PSP as it targets neuronal survival rather than tau pathology directly.
Clinical Design
Trial Phases
The platform will proceed through multiple phases: